ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC)

被引：0
|
作者：
Griguolo, G. [1 ]
Braso-Maristany, F. [2 ]
Pascual, T. [3 ]
Chic, N. [4 ]
Vidal, M. [4 ]
Adamo, B. [4 ]
Giarratano, T. [1 ]
Dieci, M. V. [5 ]
Guarneri, V. [5 ]
Prat, A. [2 ]
机构：
[1] Ist Oncol Veneto IRCCS, Med Oncol 2, Padua, Italy
[2] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain
[3] SOLTI Breast Canc Cooperat Grp, Barcelona, Spain
[4] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
[5] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
20P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
    Yu, Yongchao
    Wang, Jin
    Liao, Dongying
    Zhang, Dou
    Li, Xiaojiang
    Jia, Yingjie
    Kong, Fanming
    BREAST CANCER-TARGETS AND THERAPY, 2022, 14 : 417 - 432
  • [22] Relative efficacy of antibody-drug conjugates and other anti-HER2 treatments on survival in HER2-positive advanced breast cancer: a systematic review and meta-analysis
    Kang, Zian
    Jin, Yuqing
    Yu, Huihui
    Li, Su
    Qi, Yingjie
    BMC CANCER, 2024, 24 (01)
  • [23] Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem
    Wahdan-Alaswad, Reema
    Liu, Bolin
    Thor, Ann D.
    CANCER DRUG RESISTANCE, 2020, 3 (02) : 179 - 198
  • [24] Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low
    Fan, Pinchao
    Xu, Kun
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (01):
  • [25] Current and Emerging Role of Antibody-Drug Conjugates in HER2-Negative Breast Cancer
    Abelman, Rachel Occhiogrosso
    Keenan, Jennifer C.
    Ryan, Phoebe K.
    Spring, Laura M.
    Bardia, Aditya
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 151 - 167
  • [26] Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer
    Zimmerman, Brittney S.
    Esteva, Francisco J.
    CANCERS, 2024, 16 (04)
  • [27] Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
    Ji, Chenchen
    Li, Feng
    Yuan, Yang
    Zhang, Huiqiang
    Bian, Li
    Zhang, Shaohua
    Wang, Tao
    Li, Jianbin
    Jiang, Zefei
    ONCOLOGIST, 2023, 28 (10): : e859 - e866
  • [28] ANTI-HER2 ANTIBODY-DRUG CONJUGATES INDUCING INTERSTITIAL LUNG DISEASE - IS STEROID ALWAYS THE RIGHT ANSWER FOR THE TREATMENT?
    Khan, Anosh A.
    Khan, Mahrukh
    Yarrarapu, Siva Naga S.
    Alrjoob, Montaser
    Khalid, Farhan
    Tayyeb, Muhammad
    Weiner, Sharon M.
    CHEST, 2023, 164 (04) : 4863A - 4864A
  • [29] Antibody-drug conjugates (ADC special)-part 2: New therapy options in lung and breast cancer
    Gampenrieder, Simon
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2024, 17 (03) : 156 - 157
  • [30] Creating a superior, site-specific anti-HER2 antibody-drug conjugate (NG-HER2 ADC) for treatment of solid tumors
    Ma, Dangshe
    Narayanan, Bitha
    Marquette, Kim
    Graziani, Edmund
    Loganzo, Frank
    Charati, Manoj
    Prashad, Nadira
    Tumey, Nathan
    Golas, Jon
    Hosselet, Christine
    Hu, George
    Barletta, Frank
    Betts, Alison
    Lucas, Judy
    O'Donnell, Chris
    Tchistiakova, Lioudmila
    Gerber, Hans-Peter
    Sapra, Puja
    CANCER RESEARCH, 2016, 76
12345